Reflecting the overall structural alterations in the tissue, changes in the flow of interstitial fluid in articular cartilage could be an indicator revealing the onset of osteoarthritis, according to a new study from the University of Eastern Finland.
The PhD study of Janne Mäkelä , MSc, focused on structural and functional changes in articular cartilage at different stages of osteoarthritis. By using finite element modelling, the study combined structural data with functional data measured from articular cartilage samples. This enabled a detailed analysis of how individual structural components affect cartilage loading, and how this process changes in the development of osteoarthritis. read more
ASTRAZENECA’S COMBINATION OF DURVALUMAB WITH TREMELIMUMAB SHOWS CLINICAL ACTIVITY IN NON-SMALL CELL LUNG CANCER IRRESPECTIVE OF PD-L1 STATUS
LONDON–(BUSINESS WIRE)–AstraZeneca and MedImmune, its global biologics research and development arm, today announced publication in The Lancet Oncology of a Phase Ib study (study 006), showing antitumour activity of combination treatment with durvalumab and tremelimumab, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of PD-L1 status.1 read more
Global Myelodysplastic Syndrome Market 2015-2019 with Celgene, Novartis & Otsuka Dominating – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Myelodysplastic Syndrome Market 2015-2019” report to their offering.
The global myelodysplastic syndrome market to grow at a CAGR of 9.93% during the period 2015-2019.
Global Myelodysplastic Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Government organizations and pharmaceutical companies are conducting awareness programs to spread knowledge about the disease and associated drugs. In addition, they are also providing patient assistance programs to give low-income people with myelodysplastic syndrome access to these drugs. These two factors will surge the number of people availing treatment services, increasing the sales and consumption of drugs.
According to the report, the immune system of an individual deteriorates as aging progresses. For this reason, people aged 60 and above are more susceptible to this disease. A surge in the population of this age group will increase the need for treatment drugs, positively influencing the latter’s sales and revenue.
MGB Biopharma and University of Strathclyde Sign New Agreement to Develop Novel MGB Anti-Infectives to Tackle a Key Mechanism of AMR
New compounds designed to overcome efflux pump mediated bacterial resistance
MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem of antibiotic resistance, and the University of Strathclyde (UoS), today announced that they have agreed terms to extend their collaboration and to a Licence Option Agreement (“Agreement”) that aims to develop novel MGB anti-infectives designed to overcome efflux pump mediated bacterial resistance, commonly seen in Gram-negative pathogens. The Agreement provides MGB Biopharma access to additional intellectual property (IP) owned by UoS relating to DNA Minor Groove Binders. For more information please visit http://www.mgb-biopharma.com.
Ferring announces the start of the PRONOUNCE Trial for patients with advanced prostate cancer and cardiovascular disease receiving degarelix or leuprolide
SAINT PREX, Switzerland–(BUSINESS WIRE)–Ferring Pharmaceuticals announced today the commencement of the Phase 3b PRONOUNCE Trial. The trial will compare the occurrence of major adverse cardiovascular events (MACEs) in patients with prostate cancer and cardiovascular disease (CVD), receiving the GnRH receptor antagonist, degarelix, to patients receiving a GnRH receptor agonist, leuprolide. read more
Philogen Announces Expanded Research and Development Agreement with AbbVie
‘We are excited to expand our collaboration with AbbVie, a leader in the field of antibody therapeutics’’ commented Dr. Duccio Neri, Philogen’s CEO. ‘The first agreement between the companies focused on osteoarthritis, and we are continuing to explore the shared scientific strengths of both companies.’’
No financial details of the agreement were released.
Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information please visit http://www.philogen.com
JHL Biotech Receives Approval From European Authorities to Begin Biosimilar Clinical Trial
2016 /PRNewswire/ — JHL Biotech, Inc. (Stock Code: 6540.TWO) announced it has received authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) to begin clinical trial for JHL1101, a rituximab biosimilar developed and manufactured by its Taiwanese subsidiary to treat rheumatoid arthritis. JHL is the first company from the Greater China region to receive European approval for clinical trial of a monoclonal antibody biosimilar.